Open AccessVedolizumab response in inflammatory bowel disease. Two years of follow-up
Author(s) -
Pilar Del Pino Bellido,
María Belvis Jiménez,
Luisa Castro Laria,
María Belén Maldonado Pérez,
Antonia Sáez Díaz,
Ángel Caunedo Álvarez,
Federico ArgüellesArias
Publication year - 2020
Publication title -
revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.7130/2020
Subject(s) - vedolizumab , medicine , inflammatory bowel disease , gastroenterology , inflammatory bowel diseases , disease
vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom